

A mathematical model for understanding and controlling monkeypox transmission dynamics in the United States and its implications for future epidemic management

Md. Azmir Ibne Islam^{a,*}, M H M Mubassir^{a,b}, Arindam Kumar Paul^c, Sharmin Sultana Shanta^c

^a*Department of Mathematics and Natural Sciences, Brac University, 66 Mohakhali, Dhaka 1212, Bangladesh*

^b*Institute of Bioinformatics, University of Georgia, USA*

^c*Mathematics Discipline, Khulna University, Khulna 9208, Bangladesh*

*Corresponding author: azmir.islam@bracu.ac.bd (M A I Islam)

Abstract

Although the outbreak of human monkeypox (Mpox) caused by the monkeypox virus (MPXV) has slowed down around the world, little is known about this epidemic-like disease. To identify and re-examine the underlying pattern of the disease through a modified logistic growth model, Mpox data set of the United States from 10 May 2022 to 31 December 2022 was used in this study. The main focus is on the two non-pharmaceutical interventions (policies for reducing human-to-human, and animal-to-human transmissions) which were applied to understand their significance on the epidemic. The interventions are used as control parameters in the model with a view to analyzing the strengths of such controls in minimizing the infected cases. The model reveals a complying acceptance to the United States data. The findings disclose that preventive measures could play important roles in controlling the deadly spread of the transmission in the year of 2022. During the transmission period, better outcomes could have been possible to achieve in the US if both controls were brought to action simultaneously. Our model reflects that to prevent the outbreak of Mpox and/or any similar diseases from a community in future, the continuous application of the preventive strategies displayed through the model might be an effective tool. Moreover, such strategies could play supporting roles during pre-and/or post-vaccination periods.

Keywords: Monkeypox virus (MPXV), mathematical modeling, logistic model, outbreak dynamics.

1. Introduction

For over two years, the world has suffered from the deadly viral disease COVID-19 (SARS-CoV-2). Before this pandemic ended, another old zoonotic viral disease known as monkeypox (Mpox) came to focus, which caused significant cases in 2022 [Kumar et al., 2022; Farahat et al., 2022; Zumla et al., 2022]. The Mpox disease is caused by the monkeypox virus (MPXV), an Orthopoxvirus genus virus. It was first discovered in cynomolgus monkeys

in 1958 during a study of the polio vaccine in Copenhagen, Denmark [McCollum and Damon, 2014; Jezek, 1988]. The first human Mpox disease was reported in August 1970 in Bokenda, Democratic Republic of the Congo (DRC) [Breman et al., 1980; Durski et al., 2018]. Then, through time, it became endemic in the African region [Durski et al., 2018; Reynolds et al., 2019; Levine et al., 2007].

The first Mpox outbreak outside of Africa was reported in the US in 2003. According to the Centers for Disease Control and Prevention (CDC), 72 human Mpox probable cases were registered in 2003 in the US due to close contact with pets [CDC, Reynolds et al., 2007; Guarner et al., 2004]. The UK Health Security Agency (UKHSA) documented the first non-endemic Mpox case of 2022 on May 7, 2022, and the number of cases had increased rapidly after that period [Velavan and Meyer, 2022]. On June 18, the Massachusetts Department of Public Health confirmed the first case of MPXV infection in the state and the first confirmed Mpox case in the United States in 2022 [Kraemer et al., 2022]. Following then, the number of Mpox cases in the US climbed dramatically. However, the current trend of Mpox in the US is seen to be at a stable position (low level) and around 30 thousand plus verified cases due to this disease have been documented within December 31, 2022. As of September 1, 2023, more than 89 thousand confirmed cases have been reported around the world due to Mpox [CDC].

Although MPXV is typically transmitted through animal bites or interactions, cases of 2022 outbreaks reveal varied transmission mechanisms [Antinori et al., 2022; Vivancos et al., 2022]. In 2022, most cases were discovered in non-endemic locations, but none of the patients had been to Africa. Human-to-human transmission plays a crucial role in the transmission of MPXV in such instances, which raises concern following the SARS-CoV-2 pandemic. There is also speculation that Mpox is a sexually transmitted virus that can spread among guys who typically have sex with men (MSM) [Rodriguez-Morales and Lopardo, 2022; Endo et al., 2022]. Besides human-to-human transmission, animal-to-human transmission is also responsible for the outbreak of Mpox [CDC]. The major signs of the disease include fever, rash, and lymphadenopathy, which can lead to death if it becomes complex [Le Page, 2022; Jezek et al., 1987; Huhn et al., 2005]. Other symptoms, including rectal pain and bleeding, were noted in the new outbreak for the US patients that had not previously been observed [Deresinski, 2022]. JYNNEOS is the first Mpox vaccine licensed by the Food and Drug Administration (FDA) but is only available to people at risk of exposure [Rizk et al., 2022].

Epidemiologists widely employ mathematical models as crucial tools to gain understanding of the spatial and temporal patterns of infectious diseases [Brauer et al., 2012]. Models are used to assist health authorities and governments in deciding what preventive measures are needed to put in place and how to properly allocate the health facilities with limited resources [Anderson and May, 1992]. Mathematical modeling is the technique to understand and/or forecast the dynamics of a disease [Hethcote, 2000; Diekmann and Heesterbeek, 2000; Brauer, 2008].

The current work is devoted to the well-known logistic growth model which was first introduced by P. F. Verhulst, a Belgian mathematician and biologist, who was interested in forecasting the human population of numerous nations around 1840 [Zill, 2016]. In this paper, a modified logistic growth model with two interventions is considered so that the dynamics of Mpox transmission in the United States can be understood and analyzed. The paper aims to re-examine the outbreak of Mpox in the US from 10 May 2022 to 31 December 2022 based on the daily and cumulative cases data. The ultimate focus of this work is on the effectiveness of the incorporated interventions and their implication and prospective in future epidemics.

2. Methods

2.1. Model description

The well-known logistic equation is defined as

$$\dot{y} = ry \left(1 - \frac{y}{k} \right) \quad (2.1)$$

where r is the growth rate, k is the carrying capacity and y is the population of a certain region. Since logistic equation (2.1) is frequently used to model population growth, it can be applied in modeling Mpox dynamics too.

With this view, the model (2.1) is modified as

$$\dot{y}(t) = (1-u)r y(t) \left(1 - \frac{y(t)}{1/\gamma} \right) + (1-v)h \quad (2.2)$$

In model (2.2), $y(t)$ denotes the cumulative number of infected cases due to the MPXV at time t . The parameters r and h denote the human-to-human transmission rate and zoonotic (animal-to-human) transmission rate, respectively. Due to the increase of r and h , the cumulative cases increase. The carrying capacity k is replaced by $1/\gamma$ which represents the final size of the epidemic and the parameter γ represents the treatment facility rate. The parameters of model (2.2) are listed in Table 1.

Table 1: Parameters of the model (2.2).

Parameter	Definition
r	human-to-human transmission rate
γ	treatment facility rate
h	zoonotic (animal-to-human) transmission rate

2.2. Control design with strategy

Two inputs $0 \leq u \leq 1$ and $0 \leq v \leq 1$ are introduced in model (2.2) as control parameters which have influence on the transmission rates r and h , respectively. Control 1 (i.e., u) incorporated in model (2.2) mainly signifies the strength of the interventions taken by the government for minimizing the human-to-human transmission rate whereas control 2 (i.e., v) denotes the strength of the current interventions for minimizing the animal-to-human transmission rate. Due to the influence of u and v , the rapid increase of r and h can be limited. The values of u and v closer to zero indicate the lower efficacy of control measures, whereas values closer to one signify higher efficacy. To clearly understand the effectiveness of the applied controls in mitigating the spread of monkey pox virus, the following strategies are considered: (i) Strategy 1: Implementation of control policy 1 only, (ii) Strategy 2: Implementation of control policy 2 only, and (iii) Strategy 3: Implementation of both controls simultaneously.

2.3. Model analysis

Solution of model (2.2) is

$$y(t) = \frac{1}{2} \left[A_2 - \frac{B_1}{B_2} \tanh \left(\frac{1}{2} (-B_1 B_3 c_1 - B_1 B_2 t) \right) \right] \quad (2.3)$$

where the constants are

$$c_1, A_1 = (1-u)r, A_2 = \frac{1}{\gamma}, A_3 = (1-v)h,$$

$$B_1 = \sqrt{A_1 A_2 + 4A_3}, B_2 = \sqrt{\frac{A_1}{A_2}}, B_3 = \sqrt{A_1 A_2}.$$

The equilibrium points of model (2.2) are

$$\xi_1 = \frac{A_1 A_2 + A_2 B_1 B_2}{2A_1} \quad \text{and} \quad \xi_2 = \frac{A_1 A_2 - B_1 B_3}{2A_1}.$$

2.4. Data

Model (2.2) is fitted to the US Mpox data set [CDC] in order to estimate the three parameters: r , γ and h . For data fitting, the error function E is minimized as follows

$$E = \sum_{i=1}^{236} (y(t_i) - \hat{y}(t_i))^2 \quad (2.4)$$

where $y(t_i)$ represents the model simulation results and $\hat{y}(t_i)$ denotes the US data. Moreover, $i = 1$ indicates 10 May 2022, whereas $i = 236$ signifies 31 December 2022. The values of the parameters due to the data fitting are provided in Table 2.

Table 2: Parameter values of the model (2.2).

Parameter	Value	Unit
r	0.06	per day
γ	0.000034	per day
h	5.99	per day

3. Results and Discussion

3.1. Mpox in the US

Model (2.2) fits well with the US Mpox daily and cumulative confirmed cases data from 10 May 2022 to 31 December 2022 (see Figure 1). It is seen that the peak of infection occurred in the middle of August 2022 with around 15 thousand cumulative cases (approx.). The simulation of the model (2.2) depicts that there were nearly 450 patients at the epidemic peak. By the end of 2022, around 30 thousand population became infected by MPXV.

3.2. Effect of the implementation of control policy 1

If it was possible to apply control policy 1 with 40% effectiveness, the cumulative cases could be minimized by 38% on average (see Figure 2). Due to this, there could be a delay in peak time (end of September 2022) with a peak value smaller than the baseline case. The final size could be brought down to more than 78% within the end of 2022 if control policy 1 was implemented with an efficacy level of 80%.

3.3. Effect of the implementation of control policy 2

From Figure 3, an average of 17% reduction of cumulative cases could be possible compared to the baseline case if the effectiveness of control policy 2 was 40% during the epidemic, whereas the total number of cases could be averted up to 40% if control policy 2 was 80%. Despite the variation in the efficacy level of the applied control, no significant change was seen other than the delay in peak timing.

3.4. Combined effect of the controls

Due to the implementation of both controls at the same time, significant reductions in daily cases and cumulative cases are observed (see Figure 4). If both controls were applied at 40% effectiveness, around 52% decrease in cumulative cases could be seen. On average 95% decrease in the final size could be possible if both controls were implemented with 80% efficacy level. While applying both controls at different efficacy levels, delays in the peak of infection might be observed with less patients at the peak time compared to the baseline case.

3.5. Comparison between the controls

Comparison between the two intervention policies is revealed in Figure 5. In case of single control policy, control policy 1 could be better than control policy 2 in minimizing the average number of cumulative cases from the baseline case. The total number of patients could significantly be reduced at a greater scale if both controls were implemented at the same time. Therefore, the size of the epidemic peak could possibly be shortened down with less number of patients than that of observed from the US Mpox data set [[CDC](#)].

3.6. Effect of the treatment facility

Figure 6 represents that with the enhancement of treatment facilities, the final size of the epidemic could be reduced. If the treatment facilities were enhanced by two times, the cumulative cases could be minimized up to 31% compared to the base scenario. Epidemic size could also be curtailed down to 55% with the increase of treatment facility by five times. Due to the augmentation of the treatment rate, the peak time might occur earlier with significant smaller peaks compared to the current peak.




Figure 1: Mpx in the US from 10 May 2022 to 31 December 2022. Model (2.2) was fitted to the US Mpx: (a) daily cases data, (b) cumulative cases data [CDC]. The squares with dotted line represent US dataset, red colored curves represent the model fitting.




Figure 2: Effect of control policy 1.




Figure 3: Effect of control policy 2.




Figure 4: Combined effect of control policies 1 and 2.




Figure 5: Comparison of the applied controls.




Figure 6: Effect of the treatment facility rate.

4. Conclusion

Being a zoonosis disease, human Mpox is an incessant threat to the present world as pharmaceutical outfits are still in progress. Moreover, the limited allocation of vaccines is burdening the public health sector. The JYNNEOS vaccine for Mpox prevention has recently been authorized, and criteria have been issued by the US Food and Drug Administration, which is a big step forward. However, these vaccines are only available to people at risk of exposure to the disease. Therefore, proper strategies are important, and the inspection of such strategies needs to be explored to mitigate the transmission of the MPXV and/or other related diseases.

Based on the trend of MPXV, it is evident that Mpox demands more attention. More research into generating appropriate vaccinations and antivirals is desperately needed right now. Furthermore, clinical trial data on current Mpox vaccines and antivirals are scarce. More clinical trial data is required for existing vaccines JYNNEOS and antivirals such as tecovirimat and brincidofovir. More study is needed to determine the duration of protection following the multi-dose JYNNEOS vaccination series.

The logistic model presented in this work comprises two control strategies and captures the dynamics of Mpox infection in the United States. While re-examining the US Mpox trend from 10 May 2022 to 31 December 2022, it is revealed that control strategies with a sound efficacy level could weaken the transmission flow and curb the final epidemic size. The timely implementation of preventive measures could have benefits in waning the peak size. The current study also comes up with a finding that the reduction in human-to-human transmission rate should receive much more importance than minimizing animal-to-human transmission. Therefore, in future, the focus needs to be given more on the interventions that are responsible for the decline of human-to-human transmission. The limitation of the current study is that the results found from the model may possess a trivial variation from the real scenario. With large data set, more realistic outcomes could be unveiled. Moreover, the parameter values of the current model need to be modified to re-examine and/or predict the outbreak for other regions or countries. Lastly, the present model works with only two control policies. Still, to better understand the dynamics of the disease, the model can be modified with new strategies, which is one of the future goals of the present work.

Conflicts of interest: The author declares that there have no conflicts of interest.

Acknowledgements: The authors are grateful to [Md. Saalim Shadmaan](#), [Raghib Ishraq Alvy](#) and [Muhammad Mahfuz Hasan](#) for helpful discussions while preparing this work.

Ethical approval: The study does not require any ethical approval.

Data sharing statement: All the data presented in the manuscript are publicly available.

Funding: There was no funding associated with this study.

Author contribution: MAII and MHMM designed and planned the study. MAII, AKP and SSS did the mathematical analysis. MHMM reviewed the manuscript. All authors approved the final version of the manuscript for publication.

References

- Anderson R M, May R M. Infectious diseases of humans: dynamics and control. Oxford university press; 1992.
- Antinori A, Mazzotta V, Vita S, Carletti F, Tacconi D, Lapini L E, Nicastrì E. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. *Eurosurveillance* 2022; 27: 2200421.
- Brauer F, Castillo-Chavez C, Castillo-Chavez C. Mathematical models in population biology and epidemiology. New York: Springer; 2012. doi: <https://doi.org/10.1007/978-1-4614-1686-9>
- Brauer F. Compartmental models in epidemiology. *Mathematical epidemiology*. Springer, Berlin, Heidelberg; 2008. doi: https://doi.org/10.1007/978-3-540-78911-6_2
- Breman J G, Steniowski M V, Zanutto E, Gromyko A I, Arita I. Human monkeypox, 1970-79. *Bul of WHO* 1980; 58: 165.
- CDC. US Monkeypox Case Trends. Accessed on 2 January 2022.
- Deresinski S. Monkeypox in the United States. *Inf Dis Ale* 2022; 41.
- Diekmann O, Heesterbeek J A P. *Mathematical epidemiology of infectious diseases: model building, analysis and interpretation*. John Wiley & Sons; 2000.
- Durski K N, McCollum A M, Nakazawa Y, Petersen B W, Reynolds M G, Briand S, Khalakdina A. Emergence of monkeypox-west and central Africa, 1970-2017. *Morbidity and mortality weekly report* 2018; 67: 306. doi: <https://doi.org/10.15585/mmwr.mm6710a5>
- Endo A, Murayama H, Abbott S, Ratnayake R, Pearson C A, Edmunds W J, Funk S. Heavy-tailed sexual contact networks and the epidemiology of monkeypox outbreak in non-endemic regions, May 2022. *medRxiv* 2022. doi: <https://doi.org/10.1101/2022.06.13.22276353>
- Farahat R A, Abdelaal A, Shah J, Ghozy S, Sah R, Bonilla-Aldana D K, Leblebicioglu H. Monkeypox outbreaks during COVID-19 pandemic: are we looking at an independent phenomenon or an overlapping pandemic?. *Ann of cli mic and ant* 2022; 21: 1-3. doi: <https://doi.org/10.1186/s12941-022-00518-2>
- Guarner J, Johnson B J, Paddock C D, Shieh W J, Goldsmith C S, Reynolds M G, Veterinary Monkeypox Virus Working Group. Monkeypox transmission and pathogenesis in prairie dogs. *Em inf dis* 2004; 10: 426. doi: <https://doi.org/10.3201/eid1003.030878>

- Hethcote H W. The mathematics of infectious diseases. *SIAM review* 2000; 42: 599-653. doi: <https://doi.org/10.1137/S0036144500371907>
- Huhn G D, Bauer A M, Yorita K, Graham M B, Sejvar J, Likos A, Kuehnert M J. Clinical characteristics of human monkeypox, and risk factors for severe disease. *Clinical Infectious Diseases* 2005; 41: 1742-1751. doi: <https://doi.org/10.1086/498115>
- Jezek Z, Fenner F. Human monkeypox. 1988; S. Karger Ag; 1988
- Jezek Z, Szczeniowski M, Paluku K M, Mutombo M. Human monkeypox: clinical features of 282 patients. *Journal of Infectious Diseases* 1987; 156: 293-298. doi: <https://doi.org/10.1093/infdis/156.2.293>
- Kraemer M U, Tegally H, Pigott D M, Dasgupta A, Sheldon J, Wilkinson E, Brownstein J S. Tracking the 2022 monkeypox outbreak with epidemiological data in real-time. *The Lancet Infectious Diseases* 2022. doi: [https://doi.org/10.1016/S1473-3099\(22\)00359-0](https://doi.org/10.1016/S1473-3099(22)00359-0)
- Kumar N, Acharya A, Gendelman H E, Byrereddy S N. The 2022 outbreak and the pathobiology of the monkeypox virus. *Journal of Autoimmunity* 2022; 102855. doi: <https://doi.org/10.1016/j.jaut.2022.102855>
- Le Page, M. Monkeypox: Key questions answered. 2022. doi: [https://doi.org/10.1016/S0262-4079\(22\)00914-9](https://doi.org/10.1016/S0262-4079(22)00914-9)
- Levine R S, Peterson A T, Yorita K L, Carroll D, Damon I K, Reynolds M G. Ecological niche and geographic distribution of human monkeypox in Africa. *PloS one* 2007 2: e176. doi: <https://doi.org/10.1371/journal.pone.0000176>
- McCollum A M, Damon I K. Human monkeypox. *Clinical Infectious Diseases* 2014; 58: 260-267. doi:<https://doi.org/10.1093/cid/cit703>
- Reynolds M G, Davidson W B, Curns A T, Conover C S, Huhn G, Davis J P, Damon I K. Spectrum of infection and risk factors for human monkeypox, United States, 2003. *Emerging Infectious Diseases* 2007; 13: 1332. doi: <https://doi.org/10.3201/eid1309.070175>
- Reynolds M G, Doty J B, McCollum A M, Olson V A, Nakazawa Y. Monkeypox re-emergence in Africa: a call to expand the concept and practice of One Health. *Expert review of anti-infective therapy*, 17(2), 129-139. <https://doi.org/10.1080/14787210.2019.1567330>
- Rizk J G, Lippi G, Henry B M, Forthal D N, Rizk Y. Prevention and Treatment of Monkeypox. *Drugs* 2022; 1-7. doi: <https://doi.org/10.1007/s40265-022-01742-y>
- Rodriguez-Morales A J, Lopardo G. Monkeypox: Another Sexually Transmitted Infection?. *Pathogens* 2022; 11: 713. doi: <https://doi.org/10.3390/pathogens11070713>
- Velavan T P, Meyer C G. Monkeypox 2022 outbreak: an update. *Tropical Medicine & International Health* 2022.
- Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, Hopkins S. Community transmission of monkeypox in the United Kingdom, April to May 2022. *Eurosurveillance* 2022; 27: 2200422.
- Zill D G. *Differential equations with boundary-value problems*. Cengage Learning; 2016.
- Zumla A, Valdoleiros S R, Haider N, Asogun D, Ntoumi F, Petersen E, Kock R. Monkeypox outbreaks outside endemic regions: scientific and social priorities. *The Lancet Infectious Diseases* 2022; doi: [https://doi.org/10.1016/S1473-3099\(22\)00354-1](https://doi.org/10.1016/S1473-3099(22)00354-1)